Spyre Q3 2022 Earnings Report
Key Takeaways
Aeglea BioTherapeutics reported $75.2 million in cash as of September 30, 2022. The company recognized development fee revenues of $0.2 million in the third quarter of 2022. Research and development expenses totaled $12.0 million and general and administrative expenses totaled $7.0 million for the third quarter of 2022. Net loss totaled $18.2 million for the third quarter of 2022.
Prioritized pegtarviliase program to optimize resources and maximize success.
Ongoing enrollment of cohort 3 in Phase 1/2 trial of pegtarviliase for Classical Homocystinuria.
Marketing Authorization Application for pegzilarginase for Arginase 1 Deficiency submitted by Immedica is under review by the EMA.
Corporate restructuring announced to prioritize resources and focus on the pegtarviliase program while reducing expenses.
Spyre
Spyre
Spyre Revenue by Segment
Forward Guidance
Aeglea expects its cash, cash equivalents and marketable securities will enable it to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2023.